What Source Health Economics does

Source Health Economics is a UK-based health economics and outcomes research (HEOR) consultancy founded in 2016 by Juliet Warner and David Trueman. The firm provides specialist services across health economics modelling, systematic literature reviews, advanced statistics, health technology assessment (HTA) submissions, commercialisation and pricing strategy, value communication, and tailored training. Its client base comprises pharmaceutical, biotechnology, medical device, and digital health companies — with particular depth in rare disease therapy developers — seeking to secure market access and reimbursement across UK, EU, and international markets, including via NICE, SMC, and EU Joint Clinical Assessment processes.

The company's technical capabilities are applied in service delivery rather than packaged as a product. Methodologies include cost-effectiveness modelling in Excel and R/Stata, advanced evidence synthesis techniques (network meta-analyses with time-varying indirect treatment comparisons, population-adjusted ITCs such as MAIC, STC, ML-NMR, mixture cure models, and multistate models), and patient-level data analyses for clinical and observational datasets. Notable initiatives include Project HERCULES (a multi-stakeholder Duchenne Muscular Dystrophy cost-effectiveness modelling collaboration with Duchenne UK, awarded a prestigious rare disease award in 2018) and a SCHARR partnership for independent validation of systematic review search strings. Source is part of the SCIRIS group alongside Porterhouse Insights, providing a broader evidence and market access platform of over 300 professionals.

Revenue is generated through bespoke, fee-for-service professional engagements with pricing negotiated on a project basis. The go-to-market is relationship-driven enterprise field sales, with senior leadership actively involved in business development, supported by thought leadership (HTA monthly and quarterly updates, Insights blog articles), ISPOR conference participation, and LinkedIn engagement. Two UK offices (London headquarters and Oxford) serve as the operating base, with active engagements extending to Ireland and the UAE.

Name

Source Health Economics

Legal name

Source Market Access Ltd

Website

https://source-he.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

Source Health Economics is a London-based HEOR consultancy providing health economics modelling, systematic literature reviews, HTA submissions, and market access strategy to pharmaceutical, biotech, and medical device companies seeking UK, EU, and international reimbursement.

Ownership category

akta.pro rank

Product category

Health Economics & Outcomes Research (HEOR) Consulting

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Health Services (8000), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Market Access, Pricing & Reimbursement (Evidence Generation) FSP (HLAGAOAN)

akta.pro secondary industry

International Reference Pricing (IRP) & External Price Benchmarking (HLAIAKAF)

Keywords

• Health economics consulting
• Health technology assessment
• Systematic literature review
• Market access strategy
• Economic modelling services

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. HEOR Consultancy Services: Source Health Economics generates revenue by providing fee-for-service consulting across its core disciplines: health economics and economic modelling, systematic literature reviews, statistics and evidence synthesis, health technology assessment submission development, commercialisation and pricing strategy, value communication, and training. Services are tailored to individual client projects across global EU, UK, and international markets. The company works in long-term partnership with clients, suggesting recurring engagement and project-based professional services.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Source Health Economics is a specialist HEOR consultancy that develops, synthesises, and presents evidence to support market access for new healthcare interventions. It delivers seven integrated service lines — Health Economics (economic modelling), Literature Reviews, Statistics, Commercialisation & Pricing Strategy, Health Technology Assessment, Value Communication, and Training — for pharmaceutical, biotech, and medical device clients across UK, EU, and international markets.

Product overview

Source Health Economics operates as a HEOR consultancy offering a portfolio of seven integrated service offerings: Health Economics (economic modelling), Literature Reviews (systematic and rapid reviews), Statistics (advanced statistical analyses), Commercialisation & Pricing Strategy, Health Technology Assessment (HTA submissions), Value Communication (medical writing and dossiers), and Training. These services work in combination to provide end-to-end evidence generation and market access support for pharmaceutical and biotech clients seeking reimbursement for new healthcare interventions.

Differentiator

Problem solved

Functional benefit

Products and services

• Health Economics Design, development, and strategic review of economic models for health technology assessment and market access support, delivered to pharmaceutical, biotech, and medical device clients by Source's team of over 20 health economists.
• Literature Reviews Systematic and rapid literature reviews conducted to international best practice guidelines, delivered by a team of over 20 analysts and statisticians for HTA submissions, evidence generation, and standalone SLR projects.
• Statistics Application of advanced statistical methods including evidence synthesis, network meta-analyses, patient-level data analyses, and real-world evidence research to generate robust evidence from clinical trial and observational data for pharma and biotech clients.
• Commercialisation & Pricing Strategy Development and implementation of commercialisation strategies from Phase 1 to reimbursement success, including early launch planning, market sequencing, pricing strategy formulation, and payer research, for pharma and biotech clients across global, EU, and UK markets.
• Health Technology Assessment Strategic advice and HTA submission development for UK and international agencies (including NICE), supporting pharmaceutical, biotech, and medical device clients through the full HTA submission lifecycle.
• Value Communication Medical writing services producing clear, concise written materials — global reimbursement dossiers, value messages, objection handlers, evidence summaries, and publications — led by a team of ten medical writers.
• Training Tailored training courses in health economics, economic modelling, systematic literature review, and meta-analysis, designed for pharma, biotech, and other client audiences.

Quantifiable outcome

• Flexible HTA model for Duchenne Muscular Dystrophy (Project HERCULES) developed with adaptability across interventions, patient populations, treatment effects, and methods of administration
• +3 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Three partnerships are on record, tiered core and minor.

• Duchenne UK (Project HERCULES)coreStrategic or Co-development Partner · 1 January 2019Source Health Economics participated in Project HERCULES, a unique international multi-stakeholder collaborative project initiated by Duchenne UK to develop tools and evidence to support HTA and reimbursement decisions for new treatments for Duchenne Muscular Dystrophy (DMD). The project brought together leading pharmaceutical companies, academics, patient organisations, and advisers to develop a core cost-effectiveness model and common data set. Source developed a flexible, robust cost-effectiveness model that can accommodate different interventions, patient populations, treatment effects, and methods of administration, providing a standardised framework to optimise HTA outcomes for new DMD interventions.
• SCHARR (School of Health and Related Research)minorStrategic or Co-development PartnerSource Health Economics has a strategic partnership with SCHARR (School of Health and Related Research, University of Sheffield) for the independent validation of search strings used in systematic literature reviews. This partnership ensures that SLR deliverables meet international best practice guidelines.
• SCIRIS GroupcoreStrategic or Co-development PartnerSource Health Economics is part of the SCIRIS group of companies, alongside Porterhouse Insights. SCIRIS brings together five outstanding agencies with a team of over 300 individuals dedicated to delivering evidence generation, health economics, and market access services. The group pursues combined strategies including early client engagement, AI commercialisation planning, and patient involvement in evidence generation.

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Mtech Access: UK-based market access consultancy providing HTA submissions, value communication, and payer engagement services to pharma and medical device clients. Directly comparable in size, scope, and UK market access focus.
• Adelphi Values: Manchester-based patient-centered outcomes and HEOR consultancy within the Adelphi Group, providing value communication, HTA support, and evidence synthesis to pharma. Direct competitor in UK/European market access and HTA advisory.
• York Health Economics Consortium (YHEC): University of York spin-out providing health economics research, systematic reviews, HTA submission support, and statistical analysis to pharma and public-sector clients. Direct UK specialist HEOR peer with similar academic roots and NICE-aligned capabilities.
• Remap Consulting: UK-based market access and value communication consultancy supporting pharma clients with HTA submissions, pricing strategy, and payer engagement. Comparable as a UK-focused boutique serving similar pharma/biotech clients.
• Valid Insight: Market access consultancy offering HTA submissions, value communication, and pricing strategy services to pharma and biotech clients. Directly comparable in service portfolio and client base.
• Precision HEOR: Specialist HEOR consultancy providing health economic modelling, evidence synthesis, and market access support to pharma and biotech sponsors. Comparable as a focused HEOR-only boutique competing with Source's core disciplines.
• Tolley Health Economics: UK-based health economics consultancy providing economic modelling, HTA support, and market access services to pharmaceutical clients. Comparable UK specialist HEOR peer with similar client base and methodology focus.
• Costello Medical: Cambridge, UK-based scientific consultancy offering HEOR, medical communications, evidence generation, and market access services to pharma and biotech clients. One of Source Health Economics' closest direct competitors in UK specialist HEOR advisory.

Broad incumbents

• IQVIA: Global full-service CRO with a sizable HEOR and market access practice offering economic modelling, HTA, real-world evidence, and consulting. Largest scale incumbent covering Source's offerings as part of a much broader portfolio.
• Evidera (PPD / Thermo Fisher Scientific): Large global HEOR and real-world evidence consultancy within PPD/Thermo Fisher offering health economics, market access, HTA, and evidence synthesis. Broader incumbent with global delivery and broader service portfolio than Source.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/source-heor
• Xx.com/source_he

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Source Health Economics